Immuneel Therapeutics

Executive Summary

Immuneel Therapeutics is a preclinical-stage Indian biotechnology company developing affordable autologous CAR‑T cell therapies for hematologic malignancies, with an initial focus on relapsed/refractory non‑Hodgkin lymphoma (NHL). Founded in 2020, the company leverages a proprietary cell‑engineering platform to design next‑generation CAR constructs that aim to improve potency and reduce manufacturing costs. By targeting the Indian market, where access to commercial CAR‑T therapies is limited due to high prices, Immuneel seeks to democratize cell therapy for a large underserved population. The company is headquartered in Bengaluru and has a team of 50‑200 employees. Immuneel’s strategy combines in‑house process development with potential partnerships for manufacturing scale‑up. While still preclinical, the company has likely advanced its lead candidate into IND‑enabling studies. Key upcoming milestones include filing an Investigational New Drug (IND) application with the Indian regulator (DCGI) and initiating first‑in‑human clinical trials. Success in these steps would validate its platform and position Immuneel as a pioneer in affordable CAR‑T therapy in India. Given the high unmet need and the company’s cost‑focused approach, Immuneel represents an attractive early‑stage opportunity, though execution and regulatory risks remain.

Upcoming Catalysts (preview)

• Q4 2026IND filing for lead CAR‑T candidate (anti‑CD19 for NHL)70% success
• Q2 2027First patient dosed in Phase 1 clinical trial in India60% success
• H1 2027Strategic partnership or licensing deal with a global biopharma for manufacturing or ex‑India rights40% success